Development of Newer Therapies to Treat Lifestyle Disorders and Reduce the Risk of Co-morbidities is Key to the Expansion of the European Lifestyle Disorders Therapeutics Market, Says Frost & Sullivan

LONDON, December 2 - Increasing genomic knowledge will lead to the development of improved
therapies to treat lifestyle disorders. In the near future, the European
lifestyle disorders therapeutics market is set to witness enhanced therapies
and novel drugs to treat such conditions and reduce the risk of
co-morbidities.

(Logo: www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (www.pharma.frost.com),
European Lifestyle Disorders Therapeutics Market, finds that the European
obesity therapeutics market and European erectile dysfunction therapeutics
market earned revenues of US$668.1 million and US$1234.2 million,
respectively, in 2008 and estimates this to reach US$1158.1 million and
US$2,168.2 million in 2015, respectively.

"The future is likely to witness improved therapies and novel drugs to
treat lifestyle disorders and lower the risk of co-morbidities," notes Frost
& Sullivan Programme Leader Shabeer Hussain. "However, the lack of investment
in the current financial climate has dampened the development of newer
therapies and technologies, while presenting a major challenge for small
biotechnology companies."

As preventive care and personalised medicine come to the fore, more
companies are venturing into lifestyle disorders therapeutics. These new
developments are likely to present attractive investment opportunities to
large biopharmaceutical companies.

Differing regulations are having an impact on drug launches; less
price-controlled markets generally witness quicker launches while it takes
longer in more regulated markets.

"With the increase in demand for new therapies, the degree of competition
among pharmaceutical companies is also intensifying," says Hussain. "However,
the requirement of high initial investments against the backdrop of the
global economic slowdown and heightened cost containment measures, have led
to temporary or complete halt in R&D of new drugs."

Nevertheless, the scenario is optimistic. With advancements in drug
discovery, especially in the field of genomics, proteomics and chemical
libraries, drug companies are exercising tremendous efforts to bring out
novel therapies for lifestyle disorders. This is likely to attract more
investments in the future.

"The EU healthcare system should encourage the development of drugs for
lifestyle disorders through its healthcare policy by introducing clear
reimbursement policies," advises Hussain. "Efforts should also be made to
ensure a transparent, EU-wide harmonisation of regulatory policy and an
enhanced approval process for lifestyle disorders therapeutics."

If you are interested in more information about this study, please send
an e-mail to Katja Feick, Corporate Communications, at katja.feick@frost.com,
with your full name, company name, title, telephone number, company e-mail
address, company website, city, state and country.

European Lifestyle Disorders Therapeutics Market is part of the
Pharmaceuticals & Biotechnology Growth Partnership Services programme, which
also includes research in the following markets: European Vaccines Market,
European Orphan Drugs Market and, Global Diabetes Market. All research
included in subscriptions provide detailed market opportunities and industry
trends that have been evaluated following extensive interviews with market
participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to
accelerate growth and achieve best in class positions in growth, innovation
and leadership. The company's Growth Partnership Service provides the CEO and
the CEO's Growth Team with disciplined research and best practice models to
drive the generation, evaluation, and implementation of powerful growth
strategies. Frost & Sullivan leverages over 45 years of experience in
partnering with Global 1000 companies, emerging businesses and the investment
community from 40 offices on six continents. To join our Growth Partnership,
please visit www.frost.com.

    European Lifestyle Disorders Therapeutics Market
    M3F8

    Contact:
    Katja Feick
    Corporate Communications - Europe
    P: +49(0)69-7703343
    E: katja.feick@frost.com

www.frost.com

Katja Feick of Frost & Sullivan Corporate Communications - Europe, +49(0)69-7703343, katja.feick at frost.comKatja Feick of Frost & Sullivan Corporate Communications - Europe, +49(0)69-7703343, katja.feick at frost.com